24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500

Basic InformationLatest News
Have Diabetes? Don't Lose Sight of Danger to Your EyesCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationAHA News: Controlling Diabetes Takes on Greater Urgency During COVID-19 PandemicStressful Days, Worse Blood Sugar Control for People With DiabetesAnimal Tests Point to Possible Path to Ultrafast InsulinSigns of Developing Adult Diabetes Seen as Early as Age 8: StudyDoes COVID-19 Trigger New Cases of Diabetes?Telehealth Programs Improve Blood Sugar for Rural Americans With DiabetesContinuous Glucose Monitors Help With Type 1 Diabetes at Any AgeCost of Type 1 Diabetes: $2,500 a Year With Insurance1 in 10 Hospitalized COVID-19 Patients With Diabetes Dies: StudyWhite House Announces Plan for Medicare Recipients to Get Insulin at $35 Per MonthLost Pregnancies, Diabetes May Be LinkedType 2 Diabetes Linked to Worse Mental Outcomes After StrokeSleep Apnea Tied to Raised Diabetes Risk in Black AmericansHeart Attacks, Strokes Are Declining Among People With DiabetesCould Your Contact Lenses Track, Treat Your Diabetes?AHA News: Managing Diabetes Risk in Hispanic, Asian CommunitiesObesity Is Biggest Type 2 Diabetes Risk FactorAHA News: Understanding the Risky Combination of Diabetes and the CoronavirusWhy Is Coronavirus a Bigger Worry for People With Diabetes?What People With Type 1 Diabetes Need to Know About COVID-19Family Ties Help Young Adults With Type 1 Diabetes FlourishPatch Pump Device Could Offer Cheaper Insulin DeliveryCan AI Predict Who Will Develop Diabetes?Blood Sugar Control May Aid Stroke Recovery in Diabetes PatientsBacteria May Be a Player in Diabetes Among Very ObeseNew Tool Helps Muslims With Diabetes Manage Blood Sugar During Ramadan FastWant to Help Keep Diabetes at Bay? Brush & FlossDiabetes Among U.S. Young, Especially Asians, Continues to ClimbDrug Duo Speeds Regeneration of Key Cells Lost in DiabetesMedicare Could Save Billions If Allowed to Negotiate Insulin PricesAt the Barbershop, a Trim -- and a Diabetes ScreeningCertain Diabetes Meds May Lower Gout Risk, TooBig Advances Made Against Diabetes in 2019CDC Study Breaks Down Diabetes Risk for Hispanic, Asian SubgroupsFDA Authorizes Marketing of Automated Insulin Dosing ControllerDo Processed Foods Up Your Type 2 Diabetes Risk?Changing Timing, Frequency of Meals May Help With Diabetes'Diabetes Burnout' Is Real, Here's How to CopeAs Diabetes Costs Soar, Many Turn to Black Market for HelpFDA Testing Levels of Carcinogen in Diabetes Drug MetforminMom-to-Be's Diabetes May Up Odds of Heart Disease in Her KidsPrediabetes Now Common Among Teens, Young AdultsHeart Attack at 44 Helped Her Realize Diabetes' DangersDiabetes Tougher on Women's HeartsDiabetes Technology Often Priced Out of ReachSupplements Don't Prevent Kidney Disease in Type 2 DiabeticsWhy Are Insulin Prices Still So High for U.S. Patients?Health Tip: Snacks for People With Diabetes
Related Topics

Medical Disorders

Patch Pump Device Could Offer Cheaper Insulin Delivery

HealthDay News
by By Serena Gordon
HealthDay Reporter
Updated: Apr 1st 2020

new article illustration

WEDNESDAY, April 1, 2020 (HealthDay News) -- Rising prices have grabbed headlines as people struggle to afford their lifesaving insulin, but new research may have found an alternative for people with type 2 diabetes.

The study found that combining a wearable, patch-like insulin delivery device (called the V-Go) and an older, cheaper insulin could safely help people with type 2 diabetes achieve good blood sugar control.

"For patients who need to take [long-acting and meal-time] insulins in which the cost is rising rapidly, insulin delivery devices such as the V-Go allow them to get both components from regular insulin with the same efficacy and the same safety, and with the potential of improved costs," said study lead author Dr. Pablo Mora, an endocrinologist at the Dallas Diabetes Research Center at Medical City in Texas.

Valeritas, Inc., the maker of V-Go, sponsored the study.

Mora noted that it looked only at people with type 2 diabetes. The researchers didn't study people with type 1 diabetes, which is a different disease with potentially different safety concerns, he said.

When insulin pumps were first gaining in popularity, new types of insulin -- called insulin analogs, such as Humalog or NovoLog -- had been introduced, Mora said. Typically, people using an insulin pump might wear the tubing that delivers insulin under the skin for about three days. But older human insulin -- also called regular insulin -- could clog the narrow tubing, stopping insulin delivery before three days.

"We kind of abandoned regular insulin for use in pumps because there were good alternatives. But those alternatives are very expensive now," Mora said.

For people who have trouble affording insulin analogs, regular insulin may be the only affordable option. One issue with the older insulin is that it takes longer to begin working after it's injected under the skin, Mora said.

Another concern is that this type of insulin can be associated with a higher risk of low blood sugar (hypoglycemia), said Dr. Alvin Powers, director of the Vanderbilt Diabetes Center in Nashville, Tenn.

"Analogs are better for most people on insulin, but if someone can't afford insulin, it's a no-brainer -- use regular," Powers said. He wasn't involved in the current study, but is familiar with the findings.

The study authors thought that a device like V-Go might be able to use regular insulin. The device is worn for a day and then discarded. Mora said it's not likely that any clogs blocking insulin delivery would form in that time frame.

The patch-like device delivers a steady dose of background insulin and can also deliver additional insulin at mealtime.

The study included 113 adults with type 2 diabetes who were currently using the V-Go. Their average age was 61, according to Mora. Volunteers were recruited from three medical centers.

They were randomly assigned to use either an analog insulin or regular insulin in their pump for 14 weeks.

Researchers saw a slight improvement in blood sugar control. They noted no significant differences in rates of low blood sugar.

The study was just preliminary, however. It didn't have enough participants to show if blood sugar control was better on one insulin or the other, according to Mora.

"This study adds to the evidence that some individuals with type 2 can be managed with regular insulin. But people with type 2 diabetes aren't frequently on pumps," Powers said of the new research.

But, he noted, that some people aren't good candidates for using regular insulin. These include elderly people, and those who have what's known as hypoglycemia unawareness. That means they don't feel the physical symptoms that warn someone their blood sugar level is dropping.

The study will be published in a supplemental issue of the Journal of the Endocrine Society.

More information

Learn more about using insulin from the American Diabetes Association.